ArticleAnnals of nuclear medicine2026
Early clinical experience with ⁶⁸Ga-Trivehexin PET/CT in parathyroid adenomas: a proof-of- concept imaging study.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe success of surgical treatment in Primary Hyperparathyroidism (PHPT) depends on the accurate localization of the parathyroid adenoma. Although cervical ultrasonography (USI) and ⁹⁹ᵐTc- Sestamibi scintigraphy are common methods in this context, their diagnostic performance might be limited in small, ectopically located, or biologically atypical lesions. As a novel PET agent targeting integrin αvβ6 (alpha-v beta-6), ⁶⁸Ga-Trivehexin can image biological processes associated with pathological tissue remodeling. This proof-of-concept study aimed to evaluate the feasibility and potential diagnostic contribution of ⁶⁸Ga-Trivehexin PET/CT in detecting parathyroid adenoma in patients with PHPT.
methodsThis single-center, prospective proof-of-concept study included 28 patients who had a biochemical diagnosis of PHPT. All patients underwent neck ultrasound, ⁹⁹ᵐTc-Sestamibi parathyroid scintigraphy, and ⁶⁸Ga-Trivehexin PET/CT imaging. Fine Needle Aspiration Biopsy (FNAB) and Parathyroid Hormone (PTH) washout tests were performed for some patients as clinically necessary. Histopathological findings were used as the reference standard in patients who underwent surgery. The agreement between imaging methods was evaluated with Cohen's Kappa coefficient for exploratory purposes.
resultsA total of 64.2% of the patients were female, and the mean age was 56.1 ± 11.3 years. ⁹⁹ᵐTc- Sestamibi scintigraphy was found to be positive in 60.7% of the patients, while the positivity rate for ⁶⁸Ga-Trivehexin PET/CT was 78.6%. A significant proportion of cases with negative ⁹⁹ᵐTc- Sestamibi scintigraphy showed positive lesions with ⁶⁸Ga-Trivehexin PET/CT. Statistically significant, moderate agreement levels were detected in all patients between ⁹⁹ᵐTc-Sestamibi scintigraphy and ⁶⁸Ga-Trivehexin PET/CT (kappa = 0.430; p = 0.013). A moderate level of agreement was observed between the two methods in patients with histopathologically confirmed parathyroid adenoma (kappa = 0.429; p = 0.070).
conclusionThe results of this proof-of-concept study imply that ⁶⁸Ga-Trivehexin PET/CT may be a feasible and promising imaging method for localizing parathyroid adenomas in patients with primary hyperparathyroidism. It may offer potential contributions as a complementary diagnostic tool, particularly in selected cases where conventional imaging methods are limited. Further large, multicenter studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.